HT
TGTX icon

Headlands Technologies’s TG Therapeutics TGTX Stock Holding History

Headlands Technologies’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Sell
6,886
-755
-10% -$30.9K 0.04% 484
2026
Q1 		$254K Buy
+7,641
New +$228K 0.03% 543
2025
Q1 		– Sell
-21,653
Closed -$652K – 1519
2024
Q4 		$652K Buy
21,653
+18,011
+495% +$517K 0.07% 290
2024
Q3 		$85.2K Sell
3,642
-3,338
-48% -$72.9K 0.01% 703
2024
Q2 		$124K Buy
+6,980
New +$111K 0.01% 585

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Headlands Technologies's TGTX Position: Q2 2026 in Review

Headlands Technologies reduced its TG Therapeutics (TGTX) stake by 9.9% in Q2 2026, selling an estimated $30.9K and leaving 6,886 shares worth $378K. The position accounts for 0.04% of the portfolio, ranked #484.

Headlands Technologies first reported a position in TGTX in Q2 2024 and has held it in 5 quarters since. The position peaked at $652K in Q4 2024. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Headlands Technologies held 6,886 shares of TG Therapeutics worth $378K as of Q2 2026.
  • Headlands Technologies sold 755 TG Therapeutics shares in Q2 2026, an estimated $30.9K.
  • TG Therapeutics made up 0.04% of Headlands Technologies's portfolio in Q2 2026, its #484 holding.
  • Headlands Technologies first reported a position in TG Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Headlands Technologies's TG Therapeutics position peaked at $652K in Q4 2024.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.